Biofrontera AG: Actinic keratosis, most efficiently treated by Ameluz®, recognized as occupational disease

Leverkusen, Germany, 20 September 2013 - Biofrontera AG (B8F.DU) announces that actinic keratosis, the disease for which Biofrontera`s Ameluz® is approved in the EU, was classified as an occupational disease in Germany. This was the result of the "expert medical advisory board occupational diseases" at the Federal Ministry of Labor and Social Affairs, Germany.
Actinic keratoses are superficial skin tumors, which may develop into malignant squamous cell carcinomas. The scientific rational for the classification as an occupational disease was published in the `Ministerialblatt` of the German federal government1. The medical advisory board concluded that an occupational UV exposure of 40 % above normal levels at the site of tumor formation argues for a mostly work-related cause. The acceptance as an occupational disease is contingent upon providing evidence for sufficient work-related outdoor activity, in general occurring in the following occupational groups: agriculture, forestry, fishing and marine, construction and crafts (such as roofers, carpenters, building labor, bricklayers, steel fitter, welder on bridges), road workers, garbage collectors, window cleaners, sports instructors, lifeguards, preschool teachers, mountain guides, and the like. In Germany, about two million people are employed in these occupational groups1. The statutory accident insurances are now required to create policies and forms for implementation.
As a consequence of the recognition of actinic keratosis as a work-related disease patients with multiple keratoses will now be reimbursed for the costs of treatment by the employer`s mutual insurance association. Similar to private health insurances the medical services can then be paid for individually rather than by the flat fee per patient used in German public health insurances. Photodynamic therapy is a treatment option using a drug in combination with a red light illumination. Most public insurance companies remunerate the dermatologist`s work in the procedure just by the flat fee. The recognition as an occupational disease is now providing access to this highly effective treatment option for patients with public health insurance.
Since the pivotal clinical studies for Ameluz® demonstrated the highest overall efficacy rates reported thus far, particularly when considering the long-term results2, Ameluz® will most likely benefit most from the classification of actinic keratosis as an occupational disease.
Prof. Dr. Hermann Lübbert, CEO of Biofrontera AG, commented: "Actinic keratosis is frequently not taken seriously as precursor of a dangerous form of skin cancer. The recognition as an occupational disease illustrates the different appreciation by the medical expert`s advisory board. Consequently, optimal efficacy rates should be the determining factor in selecting the appropriate therapy."

References:
1 Gemeinsames Ministerialblatt, Herausgegeben vom Bundesministerium des Innern, 64. Jahrgang, Nr. 35, 12. August 2013, Page 669
2 Dirschka et al., British Journal of Dermatology (2013) 168, pp825-836

Biofrontera AG
Biofrontera aims at attending and treating the skin, recognizing the aesthetic needs of a person`s visual reflection.
Biofrontera AG is listed on the regulated market of the Frankfurt stock exchange under the symbol B8F and the ISIN number DE0006046113.
www.biofrontera.com

This press release contains forward-looking statements based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the assumptions expressed or implied in this press release to be faulty. Given these risks, uncertainties and other factors, recipients of this document are cautioned not to place undue reliance on the forward-looking statements. Biofrontera AG disclaims any obligation to update these forward-looking statements to reflect future events or developments.

Actinic Keratosis

Actinic keratosis are common, sun-induced, premalignant lesions that increase with age. Light-complected individuals are more susceptible than those with dark complexions. Years of sun exposure are required to induce sufficient damage to cause lesions. Actinic keratosis may undergo spontaneous remission if sunlight exposure is reduced, but new lesions may appear. Patients often present with lesions that were first noticed during the summer, suggesting that the lesions may become more active after sunlight exposure.

What are the symptoms and signs of Actinic Keratosis?

Actinic keratosis begin as an area of increased vascularity, with the skin surface becoming slightly rough. Texture is the key to diagnosing early lesions. They are better recognized by palpation than by inspection. Very gradually, an adherent yellow crust forms, the removal of which may cause bleeding . Individual lesions vary in size from 3 to 6 mm. The extent of disease varies from a single lesion to involvement of the entire forehead, balding scalp, or temples. Induration, inflammation, and oozing suggest degeneration into malignancy. Keratin may accumulate and form a cutaneous horn, particularly on the superior aspects of the pinna.

What are the changes of Actinic Keratosis at cellular level?

Histologically, an actinic keratosis consists of atypical squamous cells confined to the epidermis. The follicles are not involved, so there is no follicular plugging. Penetration through the dermoepidermal junction and into the dermis indicates the development of a squamous cell carcinoma.

How is Actinic Keratosis related to squamous cell carcinoma?

After several years, a small percentage of lesions may degenerate into squamous cell carcinomas. A very low yearly transformation rate for single lesions can translate into a substantial lifetime risk of transformation for patients with several actinic keratoses. Up to 60% of squamous cell carcinomas develop from actinic keratosis. Squamous cell carcinomas that evolve from actinic keratosis are not aggressive, but may eventually metastasize. All patients with actinic keratosis should be examined carefully for basal cell carcinomas.

What about Actinic Keratosis treatment?

Because actinic keratoses sometimes undergo spontaneous remission, definitive treatment may be delayed for patients with a few superficial lesions. Small lesions should be reexamined at a later date for spontaneous remission. Patients should make every effort to prevent further sun damage. This does not mean that patients must hibernate for a lifetime, but they should understand techniques to reduce sunlight exposure.

Cryotherapy.

Cryotherapy is the treatment of choice for most isolated, superficial, actinic keratoses. Actinic keratosis resides in the epithelium. Cryotherapy with liquid nitrogen causes the separation of the epidermis and dermis, resulting in a highly specific, nonscarring method of therapy for superficial lesions. Patients with darker complexions may develop hypopigmented areas after freezing, and treating multiple lesions on the faces of such patients may result in white-spotted faces. 5-FU is the best alternative.

Surgical removal.

Individual indurated lesions or those with thick crusts should be removed with minor surgical procedures. It is unnecessary to biopsy lesions less than 0.5 cm. Larger lesions or those occurring about or on the vermilion border of the lips should be examined. Electrodesiccation and curettage easily remove small, thicker lesions. The CO2 laser may be superior to vermilionectomy for actinic cheilitis too extensive to be treated with topical 5-FU.

Tretinoin.
Experience is accumulating that tretinoin (Retin-A) used alone or in combination with topical 5-FU is an effective treatment for certain actinic keratoses. Patients with mild actinic damage who show only erythema and scaling may be treated with tretinoin 0.05% to 0.1% cream applied once a day. If a few focal areas of scale do not respond after 2 to 4 months, they can be treated with cryotherapy. Tretinoin slightly enhances the effectiveness of 5-FU, thereby shortening treatment time, but intensifying tissue reaction and discomfort. Combination therapy is probably not worth the trouble.

Sunscreens.

Regular use of sunscreens prevents the development of solar keratoses. Sunscreens that contain a combination of ingredients to block both the UVA and UVB spectrum of ultraviolet light are most effective. Shade UVA Guard and DuraScreen 30 are examples of commercially available, broad spectrum sunscreens. Sunscreens are best applied in the morning on days when sun exposure is anticipated. Sunscreens should be applied to the face, lower lip, ears, back of the neck, and backs of the hands and forearms. Hats should cover bald heads. The physician should explain that although sunscreens are used, additional lesions may occur, but that many superficial areas of involvement may actually improve.

Acid peels.

Glycolic acid is an alpha hydroxy acid that is useful as a chemical peeling agent. Actinic keratoses involve epidermal hyperplasia and retention of stratum corneum. Alpha hydroxy acids applied topically in high concentrations (30% to 70% glycolic acid) cause epidermolysis and elimination of keratosis. Fluorouracil cream may be used for 5 to 7 days prior to the peel to "light up" and identify the lesions. Glycolic acid is applied with a cotton swab to the keratoses, is left on for 5 to 10 minutes, and is then removed with alcohol. Trichloroacetic acid (35%) and Jessner's solution (14 g of resorcinol, 14 g of lactic acid, and 14 g of salicylic acid dissolved in ethanol to make a final solution of 100 ml) induce a medium-depth peel and equal fluorouracil in efficacy.

Topical chemotherapy with 5-fluorouracil.

5-FU is an effective topical treatment for superficial actinic keratosis. Thicker lesions, especially those on the scalp, may evolve into squamous cell carcinomas and should be treated with more aggressive techniques. The agent is incorporated into rapidly dividing cells, resulting in cell death. Normal cells are less affected and clinically appear to be unaffected. Inflammation is induced during this process. Thick, indurated lesions become most inflamed and may best be managed by surgically removing them before instituting topical chemotherapy. discomfort may be experienced for 1 week or more during periods of intense inflammation. Pain can be minimized if only small areas are treated at one time; however, many patients wish to treat the full face instead of prolonging the unsightly erythema and crusting for weeks. Lesions on the back of the hands and arms require longer periods of treatment than those on the face. Patients with a small number of lesions may be treated during the summer or winter. Patients with a large number of lesions who work outdoors are best treated in the winter. Pharmaceutical companies that manufacture 5-FU supply patient information sheets with color photographs of the various stages of inflammation.

[http://obesityinformation.wordpress.com]

http://champix4u.blogspot.com

Article Source: http://EzineArticles.com/?expert=Jwesly_Stifen

Article Source: http://EzineArticles.com/1224064